No other cancer therapy target class caused more excitement than the programmed death-1 (PD-1) pathway related. Antibodies against PD-1 and PD-1 ligands represent a therapeutic breakthrough and are the first examples of broadly efficacious and durable cancer immunotherapies. Cancer for the first time seems to have transformed from an often incurable to a "clinically manageable" disease.
Keywords: antibodies; cancer immunotherapy; immune checkpoint; programmed death 1; protein-protein interactions.
Copyright © 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.